For patients with completely resected pancreatic cancer, adjuvant therapy with fluorouracil(Drug information on fluorouracil)/folinic acid is as effective as gemcitabine(Drug information on gemcitabine), according to the largest randomized controlled trial to date of adjuvant therapy in this disease, conducted by the European Study Group for Pancreatic Cancer.
The group's previously reported ESPAC-1 study showed a survival advantage for adjuvant 5-FU/folinic acid, and in 2007, the Charite Onkologie Clinical Studies in GI Cancer CONKO-001 study established gemcitabine (Gemzar) as the standard of care for advanced pancreatic cancer. Building on these results, the ESPAC investigators initiated the ESPAC-3 trial to compare the two regimens.
The phase III study enrolled 1,088 resected pancreatic cancer patients at 159 centers in 17 countries from 2000 to 2007. Patients received either folinic acid 20 mg/m2 IV bolus followed by 5-FU 425 mg/m2 IV bolus given on five consecutive days every 28 days for six cycles, or IV gemcitabine 1,000 mg/m2 once weekly for three out of every four weeks for six cycles.
After a median follow-up of 34.2 months, overall survival did not differ between the two groups: 23.0 months with 5-FU/folinic acid and 23.6 months with gemcitabine (hazard ratio [HR] 0.94; P = .39), reported John P. Neoptolemos, MD, of the University of Liverpool and his ESPAC colleagues. Progression-free survival was14.1 months and 14.3 months, respectively (HR 0.98; P = .53) (JAMA 304:1073-1081, 2010).
Patients receiving gemcitabine had fewer treatment-related serious adverse events (52 vs 97 for those on 5-FU/folinic acid; P < .001). Grade 3-4 stomatitis and diarrhea were significantly increased in the 5-FU patients, whereas the gemcitabine patients had significantly increased grade 3-4 hematologic toxicity. Quality-of-life scores did not differ significantly between groups.
On multivariate analysis, significant independent prognostic factors for overall survival were disease grade, nodal status, tumor size, performance status, postoperative CA19-9 levels, and smoking status. Resection margin status was significant only on univariate analysis, "confirming the previous results of ESPAC-1 that primary tumor characteristics dominate outcome," the authors wrote.
The novel finding that tobacco smokers (past and present) had significantly shorter OS, compared with never smokers, "should add further weight against the use of tobacco," they noted.